Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q2 FY19 results · Jul–Sep 2018
Natco Pharma reported revenue from operations of ₹543.50 crore and net profit of ₹181.60 crore for Q2 FY19 (Jul–Sep 2018), on a consolidated basis.
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 543.50 | — | — | 538.60 | +0.9% |
| Other income | 40.00 | — | — | 35.90 | +11.4% |
| Total income | 583.50 | — | — | 574.50 | +1.6% |
| Profit before tax | 235.30 | — | — | 232.30 | +1.3% |
| Net profit for the period | 181.60 | — | — | 181.10 | +0.3% |
| Attributable to shareholders of the company | 182.50 | — | — | 181.60 | +0.5% |
| EPS, basic (₹) | 9.89 | — | — | 9.84 | +0.5% |
| Net margin (%) | 33.4 | — | 33.6 |
| Item | Q2 FY19 | Q2 FY18 | YoY | Q1 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 522.40 | — | — | 515.70 | +1.3% |
| Other income | 39.70 | — | — | 35.70 | +11.2% |
| Total income | 562.10 | — | — | 551.40 | +1.9% |
| Profit before tax | 246.80 | — | — | 239.80 | +2.9% |
| Net profit for the period | 193.10 | — | — | 188.60 | +2.4% |
| EPS, basic (₹) | 10.47 | — | — | 10.22 | +2.4% |
| Net margin (%) | 37.0 | — | 36.6 |
Consolidated
- Filed with BSE
- 07 Nov 2018, 08:58 IST
- Board meeting
- 05 Nov 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Nov 2018, 08:58 IST
- Board meeting
- 05 Nov 2018
- Period
- 01 Jul 2018 to 30 Sep 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE